Cannabis and anxiety: A critical review of the evidence

Human Psychopharmacology

Volumn 24, Issue 7, 2009, Pages 515-523

  Crippa, José Alexandre ^a,b   Zuardi, Antonio Waldo ^a,e   Martín Santos, Rocio ^b,c   Bhattacharyya, Sagnik ^b   Atakan, Zerrin ^b   McGuire, Philip ^b,f   Fusar Poli, Paolo ^b,d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSITY OF PAVIA   (Italy)

^e Department of Neurosciences and Behavior ^*

^f Neuroimaging Section

Author keywords

Anxiety; Cannabidiol; Cannabis sativa; Psychosis; Tetrahydrocannabinol

Indexed keywords

AMFEBUTAMONE; CANNABIDIOL; CANNABIS; DRONABINOL; ENDOCANNABINOID; NABILONE; NEFAZODONE; PLACEBO; TETRAHYDROCANNABINOL; VALPROATE SEMISODIUM;

AGORAPHOBIA; ANXIETY DISORDER; CANNABIS ADDICTION; CANNABIS SMOKING; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DISTRESS SYNDROME; HUMAN; MENTAL STRESS; MOOD DISORDER; NEUROMODULATION; NONHUMAN; PANIC; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SOCIAL PHOBIA; SYSTEMATIC REVIEW; WITHDRAWAL SYNDROME;

ANIMALS; ANXIETY; CANNABIS; DATABASES, BIBLIOGRAPHIC; HUMANS; MARIJUANA ABUSE;

EID: 72849125686     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1048     Document Type: Review

References (102)

1. Agosti V, Nunes E, Levin F. 2002. Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse 28: 643-652. (Pubitemid 35424551)
2. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA: Washington, DC.
3. Arendt M, Rosenberg R, Fjordback L, et al. 2007. Testing the selfmedication hypothesis of depression and aggression in cannabisdependent subjects. Psychol Med 37(7): 935-945. (Pubitemid 46993594)
4. Arseneault L, Cannon M, Witton J, Murray R. 2004. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184: 110-117. (Pubitemid 38186851)
5. Berrendero F, Maldonado R. 2002. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology 163(1): 111-117. (Pubitemid 34985320)
6. Bonn-Miller M, Zvolensky M, Bernstein A. 2007. Marijuana use motives: concurrent relations to frequency of past 30-day use and anxiety sensitivity among young adult marijuana smokers. Addict Behav 32(1): 49-62.] (Pubitemid 44708486)
7. Boydell J, van Os J, Caspi A, et al. 2006. Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychol Med 36(10): 1441-1446. (Pubitemid 44355979)
8. Boys A, Marsden J, Griffiths P, Fountain J, Stillwell G, Strang J. 1999. Substance use among young people: the relationship between perceived functions and intentions. Addiction 94: 1043-1050. (Pubitemid 29329092)
9. Braida D, Liminta V, Malabarba L, Zani A, Sala M. 2007. 5-HT(1A) receptors are involved in the anxiolytic effect of delta(9)-tetrahydrocannabinol and AM404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 555(2-3): 156-163. (Pubitemid 46048802)
10. Bricker J, Russo J, Stein M, et al. 2007. Does occasional cannabis use impact anxiety and depression treatment outcomes? Results from a randomized effectiveness trial. Depress Anxiety 24(6): 392-398. (Pubitemid 47606147)
11. Buckner J, Schmidt N, Bobadilla L, Taylor J. 2006. Social anxiety and problematic cannabis use: evaluating the moderating role of stress reactivity and perceived coping. Behav Res Ther 44(7): 1007-1015. (Pubitemid 43850421)
12. Buckner J, Schmidt N, Lang A, Small J, Schlauch R, Lewinsohn P. 2008. Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res 42(3): 230-239. (Pubitemid 350266725)
13. Budney A, Hughes J, Moore B, Vandrey R. 2004. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 161(11): 1967-1977. (Pubitemid 39441395)
14. Budney A, Vandrey R, Hughes J, Moore B, Bahrenburg B. 2007. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 86(1): 22-29. (Pubitemid 44708528)
15. Campos A, Guimarães F. 2008. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology 199(2): 223-230.
16. Chabrol H, Duconge E, Casas C, Roura C, Carey K. 2005. Relations between cannabis use and dependence, motives for cannabis use and anxious, depressive and borderline symptomatology. Addict Behav 30(4): 829-840. (Pubitemid 40516847)
17. Clough A, d'Abbs P, Cairney S, et al. 2005. Adverse mental health effects of cannabis use in two indigenous communities in Arnhem Land, Northern Territory, Australia: exploratory study. Aust N Z J Psychiatry 39(7): 612-620.
18. Compton W, Cottler L, Ben Abdallah A, Phelps D, Spitznagel E, Horton J. 2000. Substance dependence and other psychiatric disorders among drug dependent subjects: race and gender correlates. Am J Addict 9: 113-125. (Pubitemid 30419109)
19. Crippa JA, Zuardi AW, Garrido GE, et al. 2004. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29(2): 417-426. (Pubitemid 38175159)
20. D'Souza D, Perry E, MacDougall L, et al. 2004. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29(8): 1558-1572. (Pubitemid 38982249)
21. Dannon P, Lowengrub K, Amiaz R, Grunhaus L, Kotler M. 2004. Comorbid cannabis use and panic disorder: short term and long term follow-up study. Hum Psychopharmacol 19: 97-101.
22. Deas D, Gerding L, Hazy J. 2000. Marijuana and panic disorder. J Am Acad Child Adolesc Psychiatry 39(12): 1467.
23. Degenhardt L, Hall W, Lynskey M. 2001. The relationship between cannabis use, depression and anxiety among Australian adults: findings from the National Survey of Mental Health and Well-Being. Soc Psychiatry Psychiatr Epidemiol 36: 219-227. (Pubitemid 32694466)
24. Degenhardt L, HallW, LynskeyM. 2003. Exploring the association between cannabis use and depression. Addiction 98(11): 493-504.
25. Dorard G, Berthoz S, Phan O, Corcos M, Bungener C. 2008. Affect dysregulation in cannabis abusers: A study in adolescents and young adults. Eur Child Adolesc Psychiatry 17(5): 274-282.
26. Fabre L, McLendon D. 1981. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 21 (Suppl. 8-9): 377S-382S.
27. Feeney G, Connor J, Young R, Tucker J, McPherson A. 2005. Cannabis dependence and mental health perception amongst people diverted by police after arrest for cannabis-related offending behaviour in Australia. Crim Behav Ment Health 15(4): 249-260.
28. Fergusson D, Horwood L. 1997. Early onset cannabis use and psychosocial adjustment in young adults. Addiction 92: 279-296.
29. Fusar-Poli P, Crippa J, Bhattacharyya S, et al. 2009. Distinct effects of D9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 66(1): 95-105.
30. Gilder D, Lau P, Dixon M, Corey L, Phillips E, Ehlers C. 2006. Comorbidity of select anxiety, affective, and psychotic disorders with cannabis dependence in southwest california indians. J Addict Dis 25(4): 67-79.
31. Giuliani D, Ferrari F, Ottani A. 2000. The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacol Res 41(1): 47-53.
32. Glass R, Uhlenhuth E, Hartel F, Schuster C, Fischman M. 1980. A single dose study of nabilone, a synthetic cannabinoid. Psychopharmacol (Berl) 71(2): 137-142.
33. Gregg J, Small E, Moore R, Raft D, Toomey T. 1976. Emotional response to intravenous delta9tetrahydrocannabinol during oral surgery. J Oral Surg 34(4): 301-313.
34. Hall W, Solowij N. 1998. Adverse effects of cannabis. Lancet 352(9140): 1611-1616.
35. Haney M. 2005. The marijuana withdrawal syndrome: diagnosis and treatment. Curr Psychiatry Rep 7(5): 360-366.
36. Haney M, Hart C, Vosburg S, et al. 2004. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29(1): 158-170.
37. Haney M, Hart C, Ward A, Foltin R. 2003. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology 165(2): 157-165.
38. Haney M, Ward A, Comer S, Hart C, Foltin R, Fischman M. 2001. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology 155(2): 171-179.
39. Hathaway AD. 2003. Cannabis effects and dependency concerns in longterm frequent users: A missing piece of the public health puzzle. Addict Res Theory 11: 441-458.
40. Hayatbakhsh M, Najman J, Jamrozik K, Mamun A, Alati R, Bor W. 2007. Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry 46(3): 408-417. (Pubitemid 46303750)
41. Hollister L. 1986. Health aspects of cannabis. Pharmacol Rev 38(1): 1-20.
42. Ilan A, Gevins A, Coleman M, ElSohly M, De Wit H. 2005. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav. Pharmacol. 16(5-6): 487-496.
43. Ilaria R, Thornby J, FannW. 1981. Nabilone, a cannabinol derivative, in the treatment of anxiety neuroses. Curr Ther Res 29: 943-949.
44. Innamorati M, Pompili M, Ferrari V, et al. 2008. Cannabis use and the risk behavior syndrome in Italian university students: are they related to suicide risk? Psychol Rep 102(2): 577-594.
45. Iversen L. 2003. Cannabis and the brain. Brain 126: 1252-1270.
46. 9- tetrahydrocannabinol in man. Eur J Pharmacol 28: 172-177.
47. Kessler R, Berglund P, Demler O, Jin R, Merikangas K, Walters E. 2005. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62(6): 593-602. (Pubitemid 40973434)
48. Langs G, Fabish H, Fabish K, Zapotoczky H. 1997. Can cannabis trigger recurrent panic attacks in susceptible patients? Eur Psychiatry 12: 224-231.
49. Lynskey M, Heath A, Nelson E, et al. 2002. Genetic and environmental contributions to cannabis dependence in a national young adult twin sample. Psychol Med 32(2): 195-207.
50. Manzanares J, Corchero J, Fuentes J. 1999. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res 839(1): 173-179.
51. Manzanares J, Uriguen L, Rubio G, Palomo T. 2004. Role of endocannabinoid system in mental diseases. Neurotox Res 6(3): 213-224.
52. Marco E, Adriani W, Llorente R, Laviola G, Viveros M. 2009. Detrimental psychophysiological effects of early maternal deprivation in adolescent and adult rodents: Altered responses to cannabinoid exposure. Neurosci Biobehav Rev 33(4): 498-507.
53. McGee R, Williams S, Poulton R, Moffitt T. 2000. A longitudinal study of cannabis use and mental health from adolescence to early adulthood. Addiction 95: 491-503.
54. Meser K, Drake R,Wallach M. 1998. Dual diagnosis: a review of etiological theories. Addict Behav 23: 717-734.
55. Moran C. 1986. Depersonalization and agoraphobia associated with marijuana use. Br J Med Psychol 59: 187-196.
56. Moreira F, Lutz B. 2008. The endocannabinoid system: emotion, learning and addiction. Addict Biol 13(2): 196-212.
57. Muntoni A, Pillolla G, Melis M, Perra S, Gessa G, Pistis M. 2006. Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. Eur J Neurosci 23(9): 2385-2394.
58. Murray RM, Morrison PD, Henquet C, Di Forti M. 2007. Cannabis, the mind and the society; the hash realities. Nat Rev Neurosci 8(11): 885-895.
59. Naliboff B, Rickles W, Cohen M, Naimark R. 1976. Interactions of marijuana and induced stress: forearm blood flow, heart rate, and skin conductance. Psychophysiology 13(6): 517-522.
60. O'Shea M, McGregor I, Mallet P. 2006. Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. J Psychopharmacol 20(5): 611-621. (Pubitemid 44315859)
61. O'Shea M, Singh M, McGregor I, Mallet P. 2004. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol 18(4): 502-508. (Pubitemid 39665118)
62. Ogborne A, Smart R, Weber T, Birchmore-Timney C. 2000. Who is using cannabis as a medicine and why: an exploratory study. J Psychoactive Drugs 32(4): 435-443. (Pubitemid 32104614)
63. Onaivi E, Green M, Martin B. 1990. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253: 1002-1009. (Pubitemid 20209356)
64. Patel S, Cravatt B, Hillard C. 2005. Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. Neuropsychopharmacology 30(3): 497-507. (Pubitemid 40271152)
65. Patel S, Hillard CJ. 2006. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318(1): 304-311. (Pubitemid 43920770)
66. Patton G, Coffey C, Carlin J, Degenhardt L, Lynskey M, Hall W. 2002. Cannabis use and mental health in young people: cohort study. BMJ 325(7374): 1195-1198. (Pubitemid 35398781)
67. Pertwee RG. 2008. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153(2): 199-215.
68. 9 THC. Psychopharmacology 47: 141-148.
69. Phan K, Angstadt M, Golden J, Onyewuenyi I, Popovska A, de Wit H. 2008. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci 28(10): 2313-2319.
70. Prentiss D, Power R, Balmas G, Tzuang G, Israelski D. 2004. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr 35(1): 38-45. (Pubitemid 38044780)
71. Reilly D, Didcott P, Swift W, Hall W. 1998. Long-term cannabis use: characteristics of users in an Australian rural area. Addiction 93: 837-846. (Pubitemid 28287071)
72. Rosenberg M, Anthony J. 2001. Early clinical manifestations of cannabis dependence in a community sample. Drug Alcohol Depend 64(2): 123-131. (Pubitemid 32816955)
73. Roy-Byrne M, Uhde T. 1988. Exogenous factors in panic disorder: clinical and research implications. 49: 56-61.
74. Sbrana A, Bizzarri J, Rucci P, et al. 2005. The spectrum of substance use in mood and anxiety disorders. Compr Psychiatry 46(1): 6-13. (Pubitemid 39642796)
75. Schofield D, Tennant C, Nash L, et al. 2006. Reasons for cannabis use in psychosis. Aust N Z J Psychiatry 40(6): 570-574.
76. Smith M, Barch D,Wolf T, Mamah D, Csernansky J. 2008. Elevated rates of substance use disorders in non-psychotic siblings of individuals with schizophrenia. Schizophr Res 106(2-3): 294-299.
77. Spalletta G, Bria P, Caltagirone C. 2007. Differences in temperament, character and psychopathology among subjects with different patterns of cannabis use. Psychopathology 40(1): 29-34. (Pubitemid 44800460)
78. Stewart S, Karp J, Pihl R, Peterson R. 1997. Anxiety sensitivity and self-reported reasons for drug use. J Subst Abuse 9: 223-240. (Pubitemid 29381597)
79. Strike C, Urbanoski K, Rush B. 2003. Who seeks treatment for cannabisrelated problems? Can J Public Health 94: 351-354.
80. Sundram S. 2006. Cannabis and neurodevelopment: implications for psychiatric disorders. Hum Psychopharmacol 21(4): 245-254. (Pubitemid 44043768)
81. SwadiH, BobierC. 2003. Substance use disorder comorbidity among inpatient youths with psychiatric disorder. Aust N Z J Psychiatry 37: 294-298. (Pubitemid 36833759)
82. Szuster R, Pontius E, Campos P. 1988. Marijuana sensitivity and panic anxiety. J Clin Psychiatry 49(11): 427-429.
83. Thomas H. 1993. Psychiatric symptoms in cannabis users. Br J Psychiatry 163: 141-149.
84. Thomas H. 1996. A community survey of adverse effects of cannabis use. Drug Alcohol Depend 42(3): 201-207. (Pubitemid 26356554)
85. Tournier M, Sorbara F, Gindre C, Swendsen J, Verdoux H. 2003. Cannabis use and anxiety in daily life: a naturalistic investigation in a non-clinical population. Psychiatry Res 118: 1-8. (Pubitemid 36577554)
86. Trezza V, Campolongo P, Cassano T, et al. 2008. Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal behavioral study in Wistar rats. Psychopharmacology 198(4): 529-537.
87. Troisi A, Pasini A, Saracco M, Spalletta G. 1998. Psychiatric symptoms in male cannabis users not using other illicit drugs. Addiction 93(4): 487-492. (Pubitemid 28188068)
88. Tunving K. 1987. Psychiatric aspects of cannabis use in adolescents and young adults. Pediatrician 14(1-2): 83-91. (Pubitemid 17112219)
89. Van Laar M, van Dorsselaer S, Monshouwer K, de Graaf R. 2007. Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction 102(8): 1251-1260.
90. Vandrey R, Budney A, Moore B, Hughes J. 2005. A cross-study comparison of cannabis and tobacco withdrawal. Am J Addict 14(1): 54-63. (Pubitemid 40204734)
91. Vann R, Gamage T, Warner J, et al. 2008. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 94(1-3): 191-198.
92. Viveros M, Marco E, File S. 2005. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81: 331-342. (Pubitemid 40807131)
93. Windle M, Wiesner M. 2004. Trajectories of marijuana use from adolescence to young adulthood: predictors and outcomes. Dev Psychopathol 16(4): 1007-1027.
94. Witkin J, Tzavara E, Nomikos G. 2005. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 16(5-6): 315-331. (Pubitemid 41404804)
95. Wittchen H, Fröhlich C, Behrendt S, et al. 2007. Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend 88 (Suppl. 1): S60-70. (Pubitemid 46282354)
96. Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. 2005. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 29(4): 358-367. (Pubitemid 40602516)
97. Zuardi AW, Cosme RA, Graeff FG, et al. 1993. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7: 82-88. (Pubitemid 23099702)
98. Zuardi A, Crippa J, Hallak J, Moreira F, Guimaraes F. 2006. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39(4): 421-429.
99. Zuardi A, Shirakawa I, Finkelfarb E, Karniol I. 1982. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76(3): 245-250.
100. Zvolensky M, Bernstein A, Sachs-Ericsson N, Schmidt N, Buckner J, Bonn-Miller M. 2006. Lifetime associations between cannabis, use, abuse, and dependence and panic attacks in a representative sample. J Psychiatr Res 40(6): 477-486. (Pubitemid 44175410)
101. Zvolensky M, Bonn-Miller M, Bernstein A, McLeish A, Feldner M, Leen-Feldner E. 2006. Anxiety sensitivity interacts with marijuana use in the prediction of anxiety symptoms and panic-related catastrophic thinking among daily tobacco users. Behav Res Ther 44(7): 907-924. (Pubitemid 44183643)
102. Zvolensky M, Lewinsohn P, Bernstein A, et al. 2008. Prospective associations between cannabis use, abuse, and dependence and panic attacks and disorder. J Psychiatr Res 42(12): 1017-1023.